Log In
Print this Print this

CD166 PDC (CX-2009)

  Manage Alerts
Collapse Summary General Information
Company CytomX Therapeutics Inc.
DescriptionProbody drug conjugate composed of a Probody therapeutic targeting the CD166 protein antigen coupled to DM4
Molecular Target Activated leukocyte cell adhesion molecule (ALCAM) (CD166)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today